MiNK Therapeutics, Inc. (INKT): Price and Financial Metrics
INKT Price/Volume Stats
| Current price | $8.41 | 52-week high | $19.00 |
| Prev. close | $7.92 | 52-week low | $4.56 |
| Day low | $7.92 | Volume | 19,400 |
| Day high | $8.69 | Avg. volume | 38,531 |
| 50-day MA | $8.90 | Dividend yield | N/A |
| 200-day MA | $8.15 | Market Cap | 33.33M |
INKT Stock Price Chart Interactive Chart >
MiNK Therapeutics, Inc. (INKT) Company Bio
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
INKT Price Returns
| 1-mo | -15.48% |
| 3-mo | 60.50% |
| 6-mo | 11.57% |
| 1-year | -6.14% |
| 3-year | -71.10% |
| 5-year | N/A |
| YTD | 20.68% |
| 2024 | -34.87% |
| 2023 | -59.00% |
| 2022 | -41.48% |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...